Alison M. Graham - Concepedia

Author

Alison M. Graham

The Royal Melbourne Hospital

Also Known As

A M Graham, A. Graham, A. M. Graham, Alison Graham, Alison M. Graham, Timothy Lockington

Publications

415

Citations

H-Index

Concepts

All Affiliations

The Royal Melbourne Hospital Dana-Farber Cancer Institute Peter MacCallum Cancer Centre AbbVie (United States)Walter and Eliza Hall Institute of Medical Research

About

Alison M. Graham is an author at The Royal Melbourne Hospital specializing in pharmacology, medicine, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	155
2	Natural Sciences	4	4	103
3	Engineering	3	3	67
4	Biochemistry	2	2	59
5	Anesthesia	1	1	36

Alison M. Graham

Publications

338

Citations

H-Index

Page 1

	Year	Citations
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors James M. Cleary, Caio Max S. Rocha Lima, Herbert I. Hurwitz, Investigational New Drugs OncologySolid TumorsMedicinePharmacotherapyAnti-cancer Agent	2014	74
The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study Matthew S. Davids, Andrew W. Roberts, Mary Ann Anderson, Blood	2012	40
Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin Anne Marie L. Inglis, Sunita B. Sheth, Marcie J. Hursting, American Journal of Health-System Pharmacy Medicinal ChemistryOral Digoxin 0.375Pharmacological StudyBiochemistryMedicine	2002	36
Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). John F. Seymour, Matthew S. Davids, John M. Pagel, Journal of Clinical Oncology F-refractory CllImmunologyPathologyPharmacotherapyBcl-2 Inhibitor Abt-199	2013	33
Vibrationally averaged spin densities on muons and protons in the hydroxyl and ethyl radicals T. A. Claxton, Alison M. Graham, S. F. J. Cox, Hyperfine Interactions Ethyl RadicalsEngineeringNuclear PhysicsPhysicsSpin Densities	1991	32
A Cost-Benefit Analysis of the ENIGMA Trial Alison M. Graham, Paul S. Myles, Kate Leslie, Anesthesiology	2011	28
Repeated Famotidine Administration Results in a Diminished Effect on Intragastric pH in Dogs M. Katherine Tolbert, Alison M. Graham, Adesola Odunayo, Journal of Veterinary Internal Medicine	2016	25
A chemical interpretation of vibrationally induced barriers to hindered internal rotation T. A. Claxton, Alison M. Graham Journal of the Chemical Society Faraday Transactions 2 Molecular and Chemical Physics EngineeringInternal RotationMechanical EngineeringPreferred ConformationComputational Chemistry	1987	23
Effect of rifampin on the pharmacokinetics, safety and tolerability of navitoclax (ABT-263), a dual inhibitor of Bcl-2 and Bcl-X<sub>L</sub>, in patients with cancer Jiaji Yang, R. Pradhan, Lee S. Rosen, Journal of Clinical Pharmacy and Therapeutics	2014	13
Ab initio study of propyl radicals T. A. Claxton, Alison M. Graham Journal of the Chemical Society Faraday Transactions 2 Molecular and Chemical Physics Methyl GroupUhf MethodEngineeringNatural SciencesRadical (Chemistry)	1988	12

Page 1